Business Context and Reporting Period
This Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on October 10, 2017. The report addresses a significant regulatory milestone regarding the company's drug candidate, burosumab.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event rather than financial performance data.
Material Changes
On October 10, 2017, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for burosumab. Additionally, the FDA granted Priority Review status to the application.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the regulatory submission. The primary event is the acceptance of the BLA and the assignment of Priority Review, which typically accelerates the FDA's review timeline.
Investor Verification Checklist
- Verify the specific timeline for the FDA's Priority Review decision for burosumab.
- Confirm the indications and patient population covered by the accepted Biologics License Application.
- Review the full text of the press release filed as Exhibit 99.1 for additional details on the regulatory process.